I received the following circuitously from Richard Wassersug.
-Patrick
"What is known about the psychological distress of surgical castration versus long term androgen suppression with LHRH agonists or antagonists drugs?
I share with Patrick O'Shea an interest in what is in the medical literature as the peer-reviewed literature is usually built upon larger samples than N=1 personally impressions.
What surprised me is that many—perhaps most—of the public, including MDs treating prostate cancer patients, assume that surgical castration is psychologically more traumatic than chemical castration. I saw that presumption in a paper by a Harvard MD some years ago and more recently in a paper by Itty and Getzenberg. Here's the recent reference:
Asian J Androl. 2020 Jan 21. doi: 10.4103/aja.aja_139_19. [Epub ahead of print]
How do we define "castration" in men on androgen deprivation therapy?
Itty S, Getzenberg RH.
A claim made in that paper is perhaps typical of the popular presumption. So, for example, those authors assert that an orchiectomy for prostate cancer treatment "carries a psychological impact". They support that claim with one citation, but it turns out that citation is about "unilateral orchiectomy for a testicular tumor". That is a very different patient population from the advance prostate cancer population.
My impression is that the MDs, who assume that an orchiectomy is more traumatic than repeated depot injections of LHRH drugs, haven't read the literature and are projecting their own feelings upon their patient population.
So, what does the literature say?
Well, the paper that Patrick used to start this thread states:
The results of our present study have shown that bilateral orchidectomy was associated with better HRQoL and global health status with a lesser symptoms score than patients who used degarelix. The reason for a better HRQoL in the case of bilateral orchidectomy is uncertain, but this may be attributed to the lower testosterone castration level, which could reflect better disease control. Although concerns about psychological insult with surgical castration is always raised, patients that choose bilateral orchidectomy may experience less worry and concern about cancer control than patients receiving monthly degarelix injections.
It turns out that the author speculation that "patients that choose bilateral orchidectomy may experience less worry and concern about cancer control..." has already been explored in comparison to the LHRH agonists drugs. Here's the reference and the abstract:
Quality-of-Life Outcomes After Primary Androgen Deprivation Therapy: Results From the Prostate Cancer Outcomes Study
Arnold L. Potosky , Kevin Knopf , Limin X. Clegg , Peter C. Albertsen , Janet L. Stanford , Ann S. Hamilton.
J Clin Oncol. 2001 Sep 1;19(17):3750-7.
Abstract
PURPOSE: To compare health-related quality-of-life outcomes after primary androgen deprivation (AD) therapy with orchiectomy versus luteinizing hormone-releasing hormone (LHRH) agonists for patients with prostate cancer.
PATIENTS AND METHODS: Men (n = 431) newly diagnosed with all stages of prostate cancer from six geographic regions who participated in the Prostate Cancer Outcomes Study and who received primary AD therapy but no other treatments within 12 months of initial diagnosis were included in a study of health outcomes. Comparisons were statistically adjusted for patient sociodemographic and clinical characteristics, timing of therapy, and use of combined androgen blockade.
RESULTS: More than half of the patients receiving primary AD therapy had been initially diagnosed with clinically localized prostate cancer. Among these patients, almost two thirds were at high risk of progression on the basis of prognostic factors. Sexual function outcomes were similar by treatment group both before and after implementation of AD therapy. LHRH patients reported more breast swelling than did orchiectomy patients (24.9% v 9.7%, P < .01). LHRH patients reported more physical discomfort and worry because of cancer or its treatment than did orchiectomy patients. LHRH patients assessed their overall health as fair or poor more frequently than did orchiectomy patients (35.4% v 28.1%, P = .01) and also were less likely to consider themselves free of prostate cancer after treatment.
CONCLUSION: Most endocrine-related health outcomes are similar after surgical versus medical primary hormonal therapy. Stage at diagnosis had little effect on outcomes. These results provide representative information comparing surgical and medical AD therapy that may be used by physicians and patients to inform treatment decisions.
Note—What I highlighted above. It is consistant with what is now reported for degarelix.
The issues also gets raised about the irreversibility of a surgical castration. But that also doesn't apply to the advanced prostate cancer patient with metastatic disease, who is likely to be on some androgen suppressing medications for the rest of his life.
However, suppose a patient with castrate levels of testosterone want to go back on testosterone perhaps because he can't stand androgen suppression or is adventurous and wants to explore "bipolar androgen therapy". My view is that taking testosterone as a topical gel is far easier than having to get regular depot injection of LHRH drugs.
So, in sum, for the specific population of advanced prostate cancer patients, voluntary surgical castration has NOT been shown to be more psychologically stressful that androgen suppression with depot injects of LHRH agonist or the antagonist degarelix.
This doesn't mean that I am personally endorsing one treatment over the other. Nor am I willing to assume that what is least stressful for an advanced prostate cancer patient would apply to other populations, such as testicular cancer patients or transsexuals.
---------------------
As a postscript, the Itty and Getzenberg paper has other problems. For example, it is not up to date on the use of transdermal estradiol at an ADT option. Those authors don't cite any of they papers of transdermal estradiol and they don't seem aware of the PATCH study in the UK.
Richard Wassersug
LIFEonADT.com